Fresenius SE & Co KGaA (FREG.DE)
* Ceo says we have no assets to sell; overheated m&a market is no reason to sell assets Further company coverage:
FRANKFURT, April 29 - German healthcare group Fresenius SE lifted its full-year earnings forecast as its rivals in the U.S. generic infusion drug market grappled with supply shortages longer than expected.
MUNICH - German healthcare group Fresenius will lie in wait for an overheated healthcare deal market to cool down before making further larger acquisitions, its chief executive said.
MUNICH, April 22 - German healthcare group Fresenius will lie in wait for an overheated healthcare deal market to cool down before making further larger acquisitions, its chief executive said.
- A Reuters' analysis of statistics from the U.S. Judicial Panel on Multidistrict Litigation showed the biggest increases in recent filings over Syngenta genetically modified corn, Bayer and Janssen's blood thinner Xarelto and dialysis drugs made by Fresenius.
FRANKFURT, April 16 - German hospitals operator Rhoen Klinikum AG plans to buy back more shares and boost its dividend payout to distribute to shareholders more of the proceeds from the sale of hospitals to peer Fresenius SE .
* Says to focus on small and medium sized takeovers, not the time for large takeovers
FRANKFURT, Feb 25 - German healthcare group Fresenius SE expects its adjusted net income to rise between 9 and 12 percent at constant currencies this year, helped by additional earnings from the purchase of new hospitals and demand for healthcare services.
* Says now sees kabi organic sales growth of 5-8 percent/year, constant currency ebit growth of 6-10 percent/year in medium-term
FRANKFURT - German healthcare group Fresenius plans to raise its dividend for the 22nd year in a row after hitting its financial targets for 2014, its chief executive told the Euro am Sonntag newspaper.
Earnings vs. Estimates
Analyst Research Reports
Provider: Sadif Analytics Prime
Fresenius - Finlabo Research Equity Report: Fundamental and Technical Analysis and 6 months performance forecast
Provider: Finlabo SIM Spa
Fresenius SE & Co KGaA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Thomson Reuters StreetEvents
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.